Berlin, Germany

International CBC B2B

29-30 June 2023

ESTREL BERLIN HOTEL

Check back in September to Register

BERLIN B2B

INTERNATIONAL CANNABIS BUSINESS CONFERENCE
BERLIN 2023

29-30 JUNE 2023

SCHEDULE TBA

TUESDAY, 19 JULY 2022

  • 8:45

    Conference Overview

Alex Rogers, Executive Producer of the International Cannabis Business Conference, welcomes conference attendees and provides an overview of the conference schedule, including the panels and speakers that will be providing presentations and interviews. Ngaio Bealum will be the Master of Ceremonies.

Alex Rogers

Alex Rogers

CEO & EXECUTIVE PRODUCER, ICBC
Ngaio Bealum

Ngaio Bealum

CONFERENCE MASTER OF CEREMONIES
  • 8:55

    Conference Kick-Off

The momentum for cannabis reform in Europe is greater now than at any other time since the start of cannabis prohibition, and that is a direct result of the decades of hard work performed by cannabis activists. With Germany and many other countries in the region moving closer toward the implementation of adult-use legalization, it is more important than ever to support cannabis activism efforts across Europe to help ensure that policies are sensible and that legalization succeeds.

Georg Wurth

Georg Wurth

LEADER OF THE GERMAN HEMP ASSOCIATION (DHV)
  • 9:00

    Keynote Speaker - Commissioner Burkhard Blienert

Crafting historic cannabis policies in Germany

Mr. Burkhard Blienert is a member of Germany's Social Democratic Party and currently serves as Germany's Commissioner on Narcotic Drugs at the Federal Ministry of Health. Mr. Blienert will discuss the latest developments in Germany's national effort to legalize cannabis for adult use. The keynote presentation will analyze the unique challenges that the country is facing as it continues to work towards crafting and implementing the most robust and complex cannabis policy and industry infrastructure on the planet. There will be a question and answer session with the Commissioner at the conclusion of Mr. Blienert's keynote speech.

Burkhard Blienert

Burkhard Blienert

GERMAN DRUG COMMISSIONER
  • 9:30

    Five Years of Cannabis-as-Medicine-Act: The German Way

Evaluating the current state of Germany's cannabis policy and industry

Peter Homberg will discuss the milestones in the liberalization process, such as the analogous application of the "Ordinance on medical products that are radioactive or treated with ionizing radiation" (Verordnung über radioaktive oder mit ionisierenden Strahlen behandelte Arzneimittel – "AMRADV") to irradiated cannabis flowers, the decision of the ECJ of 2020 not to classify CBD as a narcotic, and the first rebate contracts between producers of medical cannabis and health insurers. In addition, I will go into which practically relevant areas are still legally unregulated.

Peter Homburg

Peter Homberg

PARTNER, DENTONS • HEAD OF EUROPEAN CANNABIS GROUP
  • 10:15

    Reform Needs in Germany's Cannabis Policies

Crafting sensible policies for medical cannabis, commercial hemp and stimulant regulation

Jürgen Neumeyer

Jürgen Neumeyer

MANAGING DIRECTOR BRANCHENVERBAND CANNABISWIRTSCHAFT E.V. (BVCW)

MODERATOR
Carlos Kasper

Carlos Kasper

MEMBER OF THE GERMAN BUNDESTAG, SOCIAL DEMOCRATIC PARTY OF GERMANY (SPD)

Kristine Lütke

Kristine Lütke

MEMBER OF THE GERMAN BUNDESTAG, FREE DEMOCRATIC PARTY

Karl Baer

Karl Bär

MEMBER OF THE BUNDESTAG FOR BÜNDNIS'90/DIE GRÜNEN

The German Cannabis Business Association (Branchenverband Cannabiswirtschaft e.V. - BvCW) is again hosting the political panel discussion to the drug policy rapporteurs of the parties from the German Bundestag. The panel discussion will include three thematic blocks. The first block will focus on the future of medical cannabis in Germany. The second block will discuss the handling of commercial hemp products with an emphasis on legal security for CBD. Lastly, the third block will be geared toward discussing the necessary framework conditions for the controlled distribution of cannabis as a stimulant for adults.

*Note: This panel will be discussed in German

  • 11:15

    Cannabis Legalization on the Horizon in Germany

How to prepare for a completely new market

Kai-Friedrich Niermann

Kai-Friedrich Niermann

JFOUNDER, KFN+ LAW OFFICE

MODERATOR
Alain Menghé

Alain Menghé

CEO AND FOUNDER, LIO PHARMACEUTICALS GMBH

Tim Feike

Tim Feike

CEO, WEECO HOLDING GMBH

Antonia Menzel

Antonia Menzel

DIRECTOR PUBLIC AFFAIRS & CORPORATE SPOKESPERSON, SANITY GROUP

Jakob Sons

Jakob Sons

CO-FOUNDER AND MANAGING DIRECTOR, CANSATIVA GROUP

The legalization of cannabis for adult use in Germany will be the most comprehensive and significant drug policy reform project that has taken place in Europe to date. It's an effort that is proving to be difficult for German politicians to initiate quickly due to various factors inside and outside of the nation's borders. That, in turn, makes it difficult for national and international cannabis companies to prepare for the new market since they do not know when legalization will actually happen and what market regulations will actually look like. This panel will discuss strategies and what to potentially expect from Germany's regulators and reform legislators regarding the future structure of Germany's emerging cannabis market.

*Note: This panel will be discussed in German

  • 12:00

    Medical Cannabis And Adult-Use Cannabis In Europe

What will the future look like for medical cannabis policy in Europe after recreational legalization?

Lily Temperton

Lily Temperton

HEAD OF ANALYSIS, HANWAY ASSOCIATES

MODERATOR
Jürgen Bickel

Jürgen Bickel

MANAGING DIRECTOR, STORZ & BICKEL

Božidar Radišic

Božidar Radišic

PROJECT MANAGER AND FOUNDER, RESEARCH NATURE INSTITUTE

Thomas Schatton

Thomas Schatton

CEO AND ONE OF THE FOUNDERS, FOUR 20 PHARMA

Adult-use cannabis legalization is on the horizon in Germany and other European countries and it's receiving a significant amount of attention. However, recreational legalization is not the only important type of cannabis reform that the European cannabis industry is waiting for. Five years after the implementation of medical cannabis in Germany, experts and healthcare professionals expect some fundamental reforms to Germany's "Cannabis As Medicine" law in addition to recreational reforms. There is a myriad of issues that patients and physicians must overcome, including and especially all of the restrictive regulations regarding reimbursement. Additionally, most patients still struggle to find doctors offering cannabis therapy. Panelists will discuss what needs to be done in order to improve safe access in Germany and at the continental level.

  • 12:30

    Considerations: Market-Entry to European Markets

Entering European markets can be tricky. Find out what to consider and what to avoid.

Tom Zuber

Tom Zuber

FOUNDER & MANAGING PARTNER, ZUBER LAWLER

MODERATOR
Guillermo Fernandez

Guillermo J. Fernandez Navarro

CO-FOUNDER S&F ABOGADOS

Martin Böttger

Martin Böttger

LAWYER & PARTNER, SKW SCHWARZ

Sanja Bonelli

Sanja Bonelli

CEO, HERBLIZ BERLIN AND NEW GARDEN PHARMA

Benedikt Sons

Benedikt Sons

CO-FOUNDER, MANAGING DIRECTOR AND CEO OF CANSATIVA GROUP

European markets have increased significantly over the last 5 years. International Expansion has become a priority again, and cannabis companies across the globe are looking to enter European Markets. Heterogeneous markets, different maturity and diverse regulatory frameworks are only a few of the aspects that need to be considered when planning market entry into Europe. Considering that internationalization requires big amounts of investment as well as perseverance, not many companies moved forward and into Europe. Local as well as international ventures are looking to get a footprint in Europe, even more with recreational reform in near sight in Germany. What do companies have to consider when entering European markets? What role does strategic local partnership and local presence play when building a European Footprint? Which considerations should be made when looking at a solid business case including local adaptation for culture, processes and regulatory requirements?

  • 13:15

    Break

  • 13:45

    The Quest for One Global Cannabis Standard

How can standards affect the global movement of cannabis goods?

Daniel Haymann

Daniel Haymann

ATTORNEY AT LAW, MLL MEYERLUSTENBERGER LACHENAL FRORIEP LTD

MODERATOR
Marie Sanchez

Marie Sanchez

PARTNER, DELCADE AVOCATS & SOLICITORS

Fleta Solomon

Fleta Solomon

CEO, LITTLE GREEN PHARMA

Dr. Cornelius Maurer

Dr. Cornelius Maurer

ECONOMIST; CO-FOUNDER AND BOARD MEMBER OF DEMECAN

There is no global Cannabis standard. Cannabis belongs into a different range of standard systems. There are local standards on a national or state level. Especially for medicinal cannabis, pharmaceutical standards and good practices are governing the processes. Some countries work based on mutual recognition of quality standards, mainly for medicinal cannabis. Even on a global INCB-level, particularly medical cannabis cultivation standards are discussed. Where are we at when it comes to global cannabis standards? What role can technology play in this, and how can technology enable compliance? What standards are the most relevant for cannabusiness? What role do standards play to facilitate the global cannabis trade.

  • 14:15

    Operating A Medical Cannabis Company Post-Recreational Legalization

What happens to medical cannabis companies that continue to operate after recreational legalization?

Lisa Haag

Lisa Haag

FOUNDER MJ_UNIVERSE

MODERATOR
Diane Scott

Diane Scott

CHAIR AND CEO, JMCC GROUP

Dave Branfman

Dave Branfman

OF COUNSEL, BRANFMAN MAYFIELD BUSTARDE REICHENTHAL LLP

Alex Revich

Alex Revich

EQUITY PARTNER AT HYBRID PHARM, CANNABIS EDUCATION & MEDICAL PARTNERSHIPS AT LOOSH BRANDS

Stephen Verbeek

Stephen Verbeek

PRESIDENT & CEO, HELLO CANNABIS

Many medical cannabis companies are not sure if they should look forward to, or fear, the legalization of recreational cannabis in Europe. Profit margins for medical cannabis companies may be negatively impacted due to fewer reimbursements and lower levels of regulations for recreational cannabis versus medical cannabis. Research and development in the medical cannabis industry are notoriously expensive. So, what is the right strategy? Sticking to medical cannabis or opening up for the recreational market? Panelists will discuss opportunities and challenges that are awaiting cannabis companies in a dual system of medical and recreational cannabis.

  • 15:00

    Global Emerging Markets

Which international cannabis markets should investors and entrepreneurs have on their radars?

Trenton Birch

Trenton Birch

CO-FOUNDER & CEO, CHEEBA AFRICA

MODERATOR
Daniel Podestá

Daniel Podestá

PARTNER AT ESTUDIO PODESTÁ

Elisabetta Faenza

Elisabetta Faenza

BOARD MEMBER, MEDICINAL CANNABIS INDUSTRY AUSTRALIA & CEO, LEAFCANN GROUP

Wisan Potprasat

Wisan Potprasat

CEO, CANNABIS MEDICAL INDUSTIAL ESTATE ASSOCIATION OF THAILAND

Carmen Doran

Carmen Doran

CEO OF HELIUS THERAPEUTICS, BOARD MEMBER OF THE NEW ZEALAND MEDICINAL CANNABIS COUNCIL

Nothing is as constant as change. This is especially true for global cannabis markets. Next to more established and developed markets like North America or Europe, a global industry is on the rise. Enabling global cannabis markets, including the trading of a diverse range of products, is critical to prevent market saturation and bottlenecks. Even some formerly pro-prohibitionist countries in Asia or the Middle East have open up to deregulating certain cannabis products in their respective countries for medicinal or personal use. Companies looking to make a global footprint need to understand their individual role in this dynamic. Which markets are on the global rise? Which markets are relevant as sales markets for which products or services, and which ones for production? What role does adapting to local programs, cultures and regulatory frameworks play? What can we as entrepreneurs and opinion leaders do to enable a global cannabis industry, especially considering the global drug convention and its restrictive and outdated policies?

  • 16:00

    The Global Cannabis Supply Chain

Learn how to position your cannabusiness for the greatest possible success in the context of the global cannabis industry

Clark Hill attorney and Cannabis Industry Group Co-Chair, Robert Hoban will discuss considerations of country-by-country legal and regulatory treatment, how to pitch to investors, the access to international capital, and the importance of accurately characterizing the global supply chain in the present and future.

Bob Hoban

Bob Hoban

PARTNER & CO-CHAIR, CANNABIS INDUSTRY GROUP, CLARK HILL LAW
  • 16:30

    Global Cannabis Update

Implications of Germany's legalization on the EU market

This presentation will provide a global, U.S. and EU perspective on cannabis demand and policy. It will also examine how German legalization is impacting both the U.S. and EU markets. Look for keen insights and areas for future growth in these highly complex, yet emerging markets.

Beau Whitney

Beau Whitney

CHIEF ECONOMIST, WHITNEY ECONOMICS
  • 17:00

    Overcoming the Challenges of the International Cannabis Supply Chain and Logistics

Developing effective supply chain strategies to meet global cannabis consumer and patient demand

When it comes to international trade of cannabis products – the supply chain and logistics implication are CRITICAL for the ability to successfully execute such transactions. Different regulations in different countries, sometimes even contradicting each other – look like a very complex MAZE to walk thru.
Additionally, the QUALITY requirements MUST be met – according to the applicable Pharma standards. As well, the need to adhere to strict SECURITY regulations.
Yoram Eshel – CEO of Cannabilog will walk you through these complexities – based on his vast experience and deep knowledge of the global cannabis arena.

Yoram Eshel

Yoram Eshel

CEO, CANNABILOG

WEDNESDAY, 20 JULY 2022

  • 9:30

    Keynote Speaker - Lewis Koski

Track And Trace For The Cannabis Supply Chain: Helping cannabis regulation work for everyone

Building a legal cannabis market foundation bears many implications. Track-and-trace technology can be a useful tool to facilitate the challenge of balancing market efficiency and security interests, while data can provide valuable insights into industry trends and best practices. Drawing from his personal experience in the public and private sector, Lewis will elaborate on lessons learned from across the pond and its implications for setting up a successful and stable market.

Lewis Koski

Lewis Koski

CHIEF STRATEGY OFFICER, METRC
  • 10:00

    Cannabis In Biotechnology

Are cannabinoids and other cannabis active ingredients a building block for the biotechnology of the future?

Marguerite Arnold

Marguerite Arnold

ENTREPRENEUR, INFLUENCER, JOURNALIST

MODERATOR
David Traylor

David Traylor

SENIOR MANAGING DIRECTOR, GOLDEN EAGLE PARTNERS

Julian Wichmann

Julian Wichmann

CEO ALGEA CARE, CO-FOUNDER BLOOMWELL GROUP

Michael Sassano

Michael Sassano

CEO & FOUNDER, SOMAÍ PHARMACEUTICALS

Cannabis and its ingredients are getting more and more relevance in pharmaceutical and biotechnology. Companies are not only looking for innovation in individual APIs, but also in novel delivery systems. Pharmaceutical companies are getting ready for the "road to finished medicines" and recently, more and more Pharma-Players have entered the market. What does the future of cannabinoids and other cannabis-derived active ingredients in life science industries hold? What kind of cutting-edge technologies and innovations are on the horizon? Is the Cannabinoid-API of the future made from real cannabis, or are these ingredients synthetically developed and sampled together in pharmaceutical laboratories across the globe?

  • 10:30

    European Adult-Use Cannabis Legalization Models

Evaluating the different approaches to legalization in Europe

Luc Richner

Luc Richner

CEO FOUNDER, CANNAVIGIA

MODERATOR
Jörg Meyer-Brenken

Jörg Meyer-Brenken

LEAD ACCOUNT MANAGER, CANNABIS EMEA, FLUENCE

Sonny Moerenhout

Sonny Moerenhout

MANAGING PARTNER, CULTIVATORS

Aldo Vidinha

Aldo Vidinha

CEO & FOUNDER, STEPWISE PHARMA & ENGINEERING

The cannabis legalization movement is as strong as ever in Europe, with multiple countries exploring the policy change after Malta became Europe's first nation to legalize cannabis for adult use at a national level. Currently, there are three approaches to legalization in Europe. The models include the creation of a completely new industry such as in Switzerland, restructuring a formerly tolerant approach through a pilot program such as in the Netherlands, and a more direct approach such as what is being pursued in Germany.

  • 11:15

    Moving Towards A Harmonized EU Regulatory Framework On Medicinal Cannabis: A Multi Stakeholder Approach

Crafting sensible regulations for a continental industry

The current regulatory framework on medicinal cannabis in Europe is highly fragmented. Such fragmentation negatively affects all the actors in the medicinal cannabis sector: it prevents the industry from fully benefiting from the European Single Market; it creates obstacles for patients to get access to safe and high-quality medicines; it puts barriers to the development of sound scientific evidence. The best way to voice the concerns and interests of the medicinal cannabis value chain is therefore through joint action.

The multi-stakeholder approach to EU policy-making on the topic of medicinal cannabis will be the focus of this presentation, explained through the experience of Medicinal Cannabis Europe (MCE), represented by Silvia Alunni, Deputy-Secretary General. Silvia will address the key aspects that MCE is focusing on – such as policymakers' engagement – and will highlight the importance of cross-stakeholder collaboration (e.g. patients, doctors, industry) to build political support and strengthen the association's advocacy activities.

Silvia Alunni

Silvia Alunni

ADVISOR EU AFFAIRS AT HAGUE CORPORATE AFFAIRS AND DEPUTY-SECRETARY GENERAL AT MEDICINAL CANNABIS EUROPE
  • 11:45

    Capture the Dream & Seize the Moment Now

Strategies and Tactics for Success in the Expanding Global Cannabis Industry

In this session, Nic Easley, CEO of 3C Consulting and Managing Director of Multiverse Capital, will walk investors and entrepreneurs through how to plan for and determine the best current and future global opportunities. Time is limited and we have never been closer than we are right now to create the great future of this once-in-a-lifetime industry genesis. Topics will include a global regulatory overview, investing in public markets vs. private companies, how to plan and prepare for M&A and IPOs, and the risks associated with this medical, agricultural, and consumer packaged goods start-up industry. Nic entered this space 16 years ago with the goal of being disruptive in order to create an environmentally, socially just, and profitable multi-generational industry and will share his passion and exclusive insights from his diverse experience from both the operational and investment sides of the cannabis industry. Nic will educate on the do's and do not's from the cannabis industry frontlines and will illuminate creative targets investors can capitalize upon now for both meaningful short-term and long-term revenue generation, ESG impact, and generation wealth accumulation. You will be inspired and trained by one of the best on how to focus and vet opportunities to create successful businesses and investments by one of the leading pioneers in the legal cannabis and will leave armed and ready to take on the world.

Nic Easley

Nic Easley

CEO 3C CONSULTING & MULTIVERSE CAPITAL MANAGING DIRECTOR
  • 12:15

    Cannabis Cultivation In Europe & Beyond

How to harmonize demand and counteract individual market saturations and over-supply-situations

Ali Jamalian

Ali Jamalian

FOUNDER SUNSET CONNECT & PRESIDENT SAN FRANCISCO CANNABIS OVERSIGHT COMMITTEE

MODERATOR
Travis Schwartz

Travis Schwartz

CEO, CO-FOUNDER OF GROW GLIDE

Alexander Abdel-Kader

Alexander Abdel-Kader

SALES MANAGER, CALI TERPENES SL

Timo Bongartz

Timo Bongartz

GENERAL MANAGER, FLUENCE

Stuart Wilcox

Stuart Wilcox

MANAGING PARTNER, NUREVELATION;
CHIEF OPERATING OFFICER, AGRIFY

Many licensed producers have started to build up capacity in Europe over the last few years. On a per country basis, each country put into place individual requirements for cultivation facilities. Germany and the Netherlands (Wietexperiment) have opted for a public tender process for country-cultivation, whereas Denmark or Portugal are governed on licensing models. Building a licensed producer is extensive in capital requirements. A common phenomenon known from Canadian or US-facilities, recently the big sale on cannabis facilities across Europe has started. Not all companies have enough liquidity (or revenue streams) to secure and maintain those operations, and a range of assets have been sold. How much of the global supply is covered from Europe? Which production countries exist and how are they performing in comparison to other (more price-competitive) markets? What does the future of cannabis production from within Europe?

  • 13:00

    Break

  • 13:45

    Future of the Global Cannabis Industry

Historic prohibition policies and a shifting political landscape

Farida Hussain

Farida Hussain

FOUNDER OF DOVETAIL CONSULTING

MODERATOR
Stefan Meyer

Stefan Meyer

FOUNDER, PHYTOFLOW GMBH

Rebecca Tapp

Rebecca Tapp

BUSINESS DEVELOPMENT MANAGER FOR ASAHI GLASSPLANT UK LTD.

Stefan Röhrl

Stefan Röhrl

CEO, HEMPGROUP INT., CO-FOUNDER WEEDO & HEMPGROUP, PRESIDENT, GUSHI CULTURE IBIZA

Viola Brugnatelli

Viola Brugnatelli

CO-FOUNDER CANNABISCIENZA SRL, CANNABISCIENTIA SA

In past centuries Europe and Asia served as the driving forces behind the stigmatization of cannabis use. What was perpetrated by Napolean and leaders in the UK at the time was that cannabis caused lethargy and altered the state of mind in a negative way, despite cannabis' potential medicinal properties, and thus was frowned upon for use in their armies. In the 1900s cannabis prohibition swept North America. Since that time, anti-cannabis propaganda and political pressure led largely by the United States pushed the world to scrutinize the use of cannabis even further. Decades of prohibition have created tremendous stigma regarding the cannabis plant and that continues to negatively impact cannabis reform and industry efforts around the world, particularly in North America. Cannabis reform is now sweeping the continent, with Canada having legalized cannabis nationwide in 2018 and Mexico on the cusp of legalization, in addition to a growing list of legal states in the U.S. This panel will discuss the potential impact of ongoing cannabis reform in North America, on Europe's cannabis reform and industry efforts and how social stigmas continue to haunt us globally in different ways.

  • 14:30

    The EU Industrial Hemp Sector

Perspectives From the European Industrial Hemp Association (EIHA)

Francesco Mirizzi

Francesco Mirizzi

SENIOR POLICY ADVISOR, EIHA

Lorenza Romanese

Lorenza Romanese

MANAGING DIRECTOR,EIHA

Where does hemp stand in Europe? What regulatory changes are expected? What markets are currently being developed?
An overview of the industrial hemp in Europe today and tomorrow.

  • 15:00

    International Cannabis Business Development Strategies

Creating strategies to succeed on a global scale in a highly competitive environment

Jamie Pearson

Jamie Pearson

PRESIDENT & CEO, BHANG INC

MODERATOR
George Terry

George Terry

EXECUTIVE VICE PRESIDENT, RAD SOURCE

Jessica Billingsley

Jessica Billingsley

AKERNA FOUNDER, CHIEF EXECUTIVE OFFICER & BOARD CHAIR; CHAIR OF THE US CANNABIS COUNCIL

George Stantcvev

George Stantcvev

CEO, COMERG

Darren MacDonald

Darren MacDonald

CEO, KOOKIJAR

Business development is about turning opportunities into long-term success. Product design, marketing, and price points can all either be opportunities to advance your cannabis company's endeavors, or they can be missed opportunities that contribute to failure. Maximizing opportunities on a global scale is particularly difficult due to constantly evolving policies and regulations from country to country, as there is currently no uniformity at the international level. Markets that already exist will continue to mature, new markets will be created in the near future, and both will create unique opportunities and challenges. Panelists will discuss how to create effective strategies to scale cannabis companies and brands in an emerging international cannabis industry that is becoming increasingly competitive.

  • 15:45

    Legacy Cannabis In Europe

Making sure that the industry has a seat at the table

Michael Knodt

Michael Knodt

FREELANCE JOURNALIST

MODERATOR
Douglas K. Gordon

Douglas K. Gordon

FOUNDER, CANEX JAMAICA

Ben Dronkers

Ben Dronkers

PRESIDENT DRONKERS GROUP, (HEMPFLAX, SENSI SEEDS, THERMO HANF)

Legacy markets in Europe are very different from North American markets, not only from the cultural dimension. Very few brands have managed to build up long-term brand recognition, except for some long-established coffee shops, some seed banks as well as certain paraphernalia or equipment producers. Legacy use in Europe itself comes from an illegal background. In the prohibitionist setting, different key players are active. The most important question for Europe is: which areas of the legacy markets can be transferred, and how can we make sure that it is the proper part and the people who are legally active for 20+ years? Are North American concepts like social-equity, amnesty or compassionate-use programs suitable for Europe? How can we keep cannabis legacy alive in Europe?

  • 16:30

    Cannabis Organizing and Lobbying

Making sure that the industry has an effective voice

Jamie Shaw

Jamie Shaw

CHIEF STRATEGIC OFFICER, CHARLIE'S PHARMERS MARKET

MODERATOR
Demitri Downing

Demitri Downing

FOUNDER OF MITA

Luna Stower

Luna Stower

CIO (CHIEF IMPACT OFFICER), ISPIRE

Matt Kumin

Matt Kumin

FOUNDER, LAW OFFICES OF MATTHEW KUMIN

Bridget Hennessey

Bridget Hennessey

WEEDMAPS VP OF PUBLIC AFFAIRS

The emerging legal cannabis industry is creating once-in-a-generation business opportunities all over the planet. As cannabis reform continues to spread to every corner of the globe, the profit potential of the cannabis industry will only increase. It is a truly critical juncture right now for the cannabis industry and its members as lawmakers and governments craft cannabis rules and regulations that will largely govern the cannabis space for decades to come. It is as vital as ever that all members of the cannabis industry organize and lobby effectively to ensure that sensible laws and regulations are implemented.

  • 17:15

    Sustainability and Safety in the Cannabis & Hemp Industries

Mitigating potential hazards in an expanding industry

Clint Younge

Clint Younge

PRESIDENT CHARLIE'S PHARMERS MARKET

MODERATOR
Jordan Wagman

Jordan Wagman

JAMES BEARD NOMINATED CHEF, BEST SELLING AUTHOR, CULINARY CANNABIS PIONEER

Kyle Georges

Kyle Georges

VICE PRESIDENT, SALES & BUSINESS DEVELOPMENT, MARATEK

Benjamin Patock

Benjamin Patock

INTERNATIONAL RELATIONS, BOVEDA

Sustainability and safety are often afterthoughts in an industry that should be pushing it to the next level. Sustainability and safety are also often a cost saver, rather than needless expenses. Safety of the final product is also a growing topic, with the consistent push towards solventless technologies, and is something that can be dove into with this discussion as well.

The best in cannabis networking!

International Cannabis Business Conference
JOIN OUR COMMUNITY

© 2014- International Conferences Group | All rights reserved